Rick Franklin

SyntheMed, Inc. engages in the development and commercialization of medical devices for therapeutic applications. It focuses on the development and commercialization of anti-adhesion, drug delivery products and other surgical implants. The company's products and product candidates, which are based on its proprietary, bioresorbable polymer technology, are primarily surgical implants designed to prevent or reduce the formation of adhesions following a broad range of surgical procedures. Its commercialization efforts have been focused on its lead product, REPEL-CV Bioresorbable Adhesion Barrier, for use in cardiac surgery. The company has changed its name from Life Medical Sciences, Inc. to SyntheMed, Inc. in May 2005. It was founded in August 1990 and is headquartered in Iselin, NJ

DMS Data Systems is an information company focused on providing data resources to companies and organizations around the globe that work in the biomedical industry and related fields. DMS products and services include the development of online subscription databases, website content monitoring, and data feeds. The DMS Data Center database provides flexible, time saving methods for identifying, monitoring, and capturing critical industry information to make more informed business decisions.

SyntheMed, Inc. engages in the development and commercialization of medical devices for therapeutic applications. It focuses on the development and commercialization of anti-adhesion, drug delivery products and other surgical implants. The company's products and product candidates, which are based on its proprietary, bioresorbable polymer technology, are primarily surgical implants designed to prevent or reduce the formation of adhesions following a broad range of surgical procedures. Its commercialization efforts have been focused on its lead product, REPEL-CV Bioresorbable Adhesion Barrier, for use in cardiac surgery. The company has changed its name from Life Medical Sciences, Inc. to SyntheMed, Inc. in May 2005. It was founded in August 1990 and is headquartered in Iselin, NJ

DMS Data Systems is an information company focused on providing data resources to companies and organizations around the globe that work in the biomedical industry and related fields. DMS products and services include the development of online subscription databases, website content monitoring, and data feeds. The DMS Data Center database provides flexible, time saving methods for identifying, monitoring, and capturing critical industry information to make more informed business decisions.

Phairson Medical Ltd. researches and develops novel biopharmaceutical products and devices. The private company is based in London, UK.

SyntheMed, Inc. engages in the development and commercialization of medical devices for therapeutic applications. It focuses on the development and commercialization of anti-adhesion, drug delivery products and other surgical implants. The company's products and product candidates, which are based on its proprietary, bioresorbable polymer technology, are primarily surgical implants designed to prevent or reduce the formation of adhesions following a broad range of surgical procedures. Its commercialization efforts have been focused on its lead product, REPEL-CV Bioresorbable Adhesion Barrier, for use in cardiac surgery. The company has changed its name from Life Medical Sciences, Inc. to SyntheMed, Inc. in May 2005. It was founded in August 1990 and is headquartered in Iselin, NJ

Phairson Medical Ltd. researches and develops novel biopharmaceutical products and devices. The private company is based in London, UK.

SyntheMed, Inc. engages in the development and commercialization of medical devices for therapeutic applications. It focuses on the development and commercialization of anti-adhesion, drug delivery products and other surgical implants. The company's products and product candidates, which are based on its proprietary, bioresorbable polymer technology, are primarily surgical implants designed to prevent or reduce the formation of adhesions following a broad range of surgical procedures. Its commercialization efforts have been focused on its lead product, REPEL-CV Bioresorbable Adhesion Barrier, for use in cardiac surgery. The company has changed its name from Life Medical Sciences, Inc. to SyntheMed, Inc. in May 2005. It was founded in August 1990 and is headquartered in Iselin, NJ

SyntheMed, Inc. engages in the development and commercialization of medical devices for therapeutic applications. It focuses on the development and commercialization of anti-adhesion, drug delivery products and other surgical implants. The company's products and product candidates, which are based on its proprietary, bioresorbable polymer technology, are primarily surgical implants designed to prevent or reduce the formation of adhesions following a broad range of surgical procedures. Its commercialization efforts have been focused on its lead product, REPEL-CV Bioresorbable Adhesion Barrier, for use in cardiac surgery. The company has changed its name from Life Medical Sciences, Inc. to SyntheMed, Inc. in May 2005. It was founded in August 1990 and is headquartered in Iselin, NJ

SyntheMed, Inc. engages in the development and commercialization of medical devices for therapeutic applications. It focuses on the development and commercialization of anti-adhesion, drug delivery products and other surgical implants. The company's products and product candidates, which are based on its proprietary, bioresorbable polymer technology, are primarily surgical implants designed to prevent or reduce the formation of adhesions following a broad range of surgical procedures. Its commercialization efforts have been focused on its lead product, REPEL-CV Bioresorbable Adhesion Barrier, for use in cardiac surgery. The company has changed its name from Life Medical Sciences, Inc. to SyntheMed, Inc. in May 2005. It was founded in August 1990 and is headquartered in Iselin, NJ

SyntheMed, Inc. engages in the development and commercialization of medical devices for therapeutic applications. It focuses on the development and commercialization of anti-adhesion, drug delivery products and other surgical implants. The company's products and product candidates, which are based on its proprietary, bioresorbable polymer technology, are primarily surgical implants designed to prevent or reduce the formation of adhesions following a broad range of surgical procedures. Its commercialization efforts have been focused on its lead product, REPEL-CV Bioresorbable Adhesion Barrier, for use in cardiac surgery. The company has changed its name from Life Medical Sciences, Inc. to SyntheMed, Inc. in May 2005. It was founded in August 1990 and is headquartered in Iselin, NJ

SyntheMed, Inc. engages in the development and commercialization of medical devices for therapeutic applications. It focuses on the development and commercialization of anti-adhesion, drug delivery products and other surgical implants. The company's products and product candidates, which are based on its proprietary, bioresorbable polymer technology, are primarily surgical implants designed to prevent or reduce the formation of adhesions following a broad range of surgical procedures. Its commercialization efforts have been focused on its lead product, REPEL-CV Bioresorbable Adhesion Barrier, for use in cardiac surgery. The company has changed its name from Life Medical Sciences, Inc. to SyntheMed, Inc. in May 2005. It was founded in August 1990 and is headquartered in Iselin, NJ